866-997-4948(US-Canada Toll Free)

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H2 2017

Published By :

Global Markets Direct

Published Date : Oct 2017

Category :

Pharmaceutical

No. of Pages : 162 Pages

Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H2 2017

Summary

Global Markets Directs latest Pharmaceutical and Healthcare disease pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H2 2017, provides an overview of the Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline landscape.

Basal cell carcinoma is a type of skin cancer which begins in the basal cells. Symptoms include waxy bump, scaly, brown or flesh-colored patch and white, waxy scar. Predisposing factors include age, family history, and exposure to radiation and immunosuppressant medications. Treatment includes chemotherapy and surgery.

Report Highlights

Global Markets Directs Pharmaceutical and Healthcare latest pipeline guide Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline Review, H2 2017, provides comprehensive information on the therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology), complete with analysis by stage of development, drug target, mechanism of action (MoA), route of administration (RoA) and molecule type. The guide covers the descriptive pharmacological action of the therapeutics, its complete research and development history and latest news and press releases.

The Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide also reviews of key players involved in therapeutic development for Basal Cell Carcinoma (Basal Cell Epithelioma) and features dormant and discontinued projects. The guide covers therapeutics under Development by Companies /Universities /Institutes, the molecules developed by Companies in Phase III, Phase II, Phase I and Preclinical stages are 3, 7, 5 and 6 respectively.

Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline guide helps in identifying and tracking emerging players in the market and their portfolios, enhances decision making capabilities and helps to create effective counter strategies to gain competitive advantage. The guide is built using data and information sourced from Global Markets Directs proprietary databases, company/university websites, clinical trial registries, conferences, SEC filings, investor presentations and featured press releases from company/university sites and industry-specific third party sources. Additionally, various dynamic tracking processes ensure that the most recent developments are captured on a real time basis.

Note: Certain content / sections in the pipeline guide may be removed or altered based on the availability and relevance of data.

Scope

- The pipeline guide provides a snapshot of the global therapeutic landscape of Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- The pipeline guide reviews pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) by companies and universities/research institutes based on information derived from company and industry-specific sources.
- The pipeline guide covers pipeline products based on several stages of development ranging from pre-registration till discovery and undisclosed stages.
- The pipeline guide features descriptive drug profiles for the pipeline products which comprise, product description, descriptive licensing and collaboration details, R&D brief, MoA & other developmental activities.
- The pipeline guide reviews key companies involved in Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics and enlists all their major and minor projects.
- The pipeline guide evaluates Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) therapeutics based on mechanism of action (MoA), drug target, route of administration (RoA) and molecule type.
- The pipeline guide encapsulates all the dormant and discontinued pipeline projects.
- The pipeline guide reviews latest news related to pipeline therapeutics for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology)

Reasons to buy

- Procure strategically important competitor information, analysis, and insights to formulate effective R&D strategies.
- Recognize emerging players with potentially strong product portfolio and create effective counter-strategies to gain competitive advantage.
- Find and recognize significant and varied types of therapeutics under development for Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology).
- Classify potential new clients or partners in the target demographic.
- Develop tactical initiatives by understanding the focus areas of leading companies.
- Plan mergers and acquisitions meritoriously by identifying key players and its most promising pipeline therapeutics.
- Formulate corrective measures for pipeline projects by understanding Basal Cell Carcinoma (Basal Cell Epithelioma) (Oncology) pipeline depth and focus of Indication therapeutics.
- Develop and design in-licensing and out-licensing strategies by identifying prospective partners with the most attractive projects to enhance and expand business potential and scope.
- Adjust the therapeutic portfolio by recognizing discontinued projects and understand from the know-how what drove them from pipeline.
Table of Contents
Table of Contents 2
List of Tables 3
List of Figures 4
Introduction 5
Global Markets Direct Report Coverage 5
Basal Cell Carcinoma (Basal Cell Epithelioma)-Overview 6
Basal Cell Carcinoma (Basal Cell Epithelioma)-Therapeutics Development 7
Pipeline Overview 7
Pipeline by Companies 8
Products under Development by Companies 11
Basal Cell Carcinoma (Basal Cell Epithelioma)-Therapeutics Assessment 13
Assessment by Target 13
Assessment by Mechanism of Action 15
Assessment by Route of Administration 17
Assessment by Molecule Type 19
Basal Cell Carcinoma (Basal Cell Epithelioma)-Companies Involved in Therapeutics Development 21
Adgero Biopharmaceuticals Holdings Inc 21
Biofrontera AG 21
Biosceptre International Ltd 21
BLR Bio LLC 22
Cannabis Science Inc 22
Genextra Spa 23
Ignyta Inc 23
Laboratories Ojer Pharma SL 23
MediGene AG 24
Medivir AB 24
Merck & Co Inc 25
Provectus Biopharmaceuticals Inc 25
Redx Pharma Plc 26
Regeneron Pharmaceuticals Inc 26
Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd 27
Transgene SA 27
Basal Cell Carcinoma (Basal Cell Epithelioma)-Drug Profiles 29
aminolevulinic acid hydrochloride-Drug Profile 29
aminolevulinic acid hydrochloride-Drug Profile 34
BIL-010t-Drug Profile 35
BLR-300-Drug Profile 36
cemiplimab-Drug Profile 37
CS-S/BCC-1-Drug Profile 40
DAC-060-Drug Profile 41
fluorouracil-Drug Profile 42
imiquimod SR-Drug Profile 43
Oshadi D + Oshadi R-Drug Profile 44
patidegib hydrochloride-Drug Profile 45
pembrolizumab-Drug Profile 48
PV-10-Drug Profile 117
RDX-001-Drug Profile 136
remetinostat-Drug Profile 137
rostaporfin-Drug Profile 140
SBT-300-Drug Profile 143
sinecatechins-Drug Profile 144
taladegib-Drug Profile 145
TG-1042-Drug Profile 147
tigilanol tiglate-Drug Profile 149
Basal Cell Carcinoma (Basal Cell Epithelioma)-Dormant Projects 151
Basal Cell Carcinoma (Basal Cell Epithelioma)-Discontinued Products 152
Basal Cell Carcinoma (Basal Cell Epithelioma)-Product Development Milestones 153
Featured News & Press Releases 153
Appendix 160
Methodology 160
Coverage 160
Secondary Research 160
Primary Research 160
Expert Panel Validation 160
Contact Us 160
Disclaimer 161

List of Tables
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Products under Development by Companies, H2 2017
Products under Development by Companies, H2 2017 (Contd..1), H2 2017
Number of Products by Stage and Target, H2 2017
Number of Products by Stage and Mechanism of Action, H2 2017
Number of Products by Stage and Route of Administration, H2 2017
Number of Products by Stage and Molecule Type, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Adgero Biopharmaceuticals Holdings Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Biofrontera AG, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Biosceptre International Ltd, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by BLR Bio LLC, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Cannabis Science Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Genextra Spa, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Ignyta Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Laboratories Ojer Pharma SL, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by MediGene AG, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Medivir AB, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Merck & Co Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Provectus Biopharmaceuticals Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Redx Pharma Plc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Regeneron Pharmaceuticals Inc, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Shanghai Fudan-Zhangjiang Bio-Pharmaceutical Co Ltd, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Pipeline by Transgene SA, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Dormant Projects, H2 2017
Basal Cell Carcinoma (Basal Cell Epithelioma)-Discontinued Products, H2 2017

List of Figures
Number of Products under Development for Basal Cell Carcinoma (Basal Cell Epithelioma), H2 2017
Number of Products under Development by Companies, H2 2017
Number of Products by Top 10 Targets, H2 2017
Number of Products by Stage and Top 10 Targets, H2 2017
Number of Products by Top 10 Mechanism of Actions, H2 2017
Number of Products by Stage and Top 10 Mechanism of Actions, H2 2017
Number of Products by Routes of Administration, H2 2017
Number of Products by Stage and Routes of Administration, H2 2017
Number of Products by Molecule Types, H2 2017
Number of Products by Stage and Molecule Types, H2 2017

Make an enquiry before buying this Report

Please fill the enquiry form below.

  • Full Name *
  • Your Email *
  • Job Title
  • Company
  • Phone No. * (Pls. Affix Country Code)
  • Message
  • Security Code *